SCHEMBL22213636

SCHEMBL22213636

COC(=O)c1cc(OCc2ccc3ccccc3c2)ccc1NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.52
MEN1 O00255 6/20 0.52
KMT2A Q03164 6/20 0.52
ALDH1A1 P00352 2/20 0.52
MAPT P10636 2/20 0.52
BLM P54132 1/20 0.52
PLAU P00749 2/20 0.49
ADAMTS4 O75173 1/20 0.49
MMP13 P45452 1/20 0.49
MCL1 Q07820 2/20 0.48
BCL2A1 Q16548 2/20 0.48
BCL2 P10415 1/20 0.48
BCL2L1 Q07817 1/20 0.48
RAPGEF3 O95398 1/20 0.48
GAA P10253 1/20 0.47
SLC16A3 O15427 1/20 0.46
LMNA P02545 1/20 0.46
KCNH2 Q12809 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
AGTR1 P30556 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22762345 0.94 MCL1 (0.53) POLBMEN1KMT2AALDH1A1MAPT
SCHEMBL22762666 0.89 MCL1 (0.60) POLBMEN1KMT2AALDH1A1MAPT
SCHEMBL22213615 0.84 MCL1 (0.64) POLBMEN1KMT2AALDH1A1MAPT
SCHEMBL22762706 0.82 NPC1 (0.48) POLBALDH1A1MAPTLMNA
SCHEMBL18151728 0.81 BCL2L1 (0.49) POLBMEN1KMT2APLAUADAMTS4
SCHEMBL18151726 0.81 KMT2A (0.67) POLBMEN1KMT2AALDH1A1PLAU
SCHEMBL18152544 0.80 PLAU (0.51) POLBMEN1KMT2AALDH1A1MAPT
SCHEMBL22213635 0.80 MEN1 (0.51) POLBMEN1KMT2AALDH1A1MAPT
SCHEMBL22213559 0.80 KDM4E (0.57) POLBMEN1KMT2AALDH1A1MAPT
SCHEMBL18151774 0.80 PLAU (0.55) POLBMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200383967-A1 Novel Anthranilic Acid-Based Compound, and Pin1 Inhibitor, Therapeutic Agent for Inflammatory Diseases and Therapeutic Agent for Cancer That Use the Same HIROSHIMA UNIVERSITY (JP) 2020-12-10 US disclosed
EP-3680232-A1 NOVEL ANTHRANILIC ACID-BASED COMPOUND, AND Pin1 INHIBITOR, THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES AND THERAPEUTIC AGENT FOR CANCER THAT USE THE SAME Hiroshima University (JP) 2020-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200383967-A1 Novel Anthranilic Acid-Based Compound, and Pin1 Inhibitor, Therapeutic Agent for Inflammatory Diseases and Therapeutic Agent for Cancer That Use the Same PIN1, NFKBIA, FKBP1A POLB 3207/4885MEN1 3660/4885KMT2A 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.